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(1.690 to 6.852); doxorubicin/congestive heart failure (1.154 to 5.004); and carmus-
tine/leukopenia (3.796 to 5.650) and thrombocytopenia (3.796 to 5.644). Further-
more, the percentage of AERS reports associated with outcomes of hospitalization
increased as follows: melphalan causing leukemia (0% to 37%, p0.001), chromo-
somal aberrations (0% to 15.55%, p0.001), bone marrow suppression (4.0% to
40.9%, p0.001), or hypersensitivity (30.77% to 50.0%, p0.01). The mortality out-
come increased only formelphalan/leukemia (8.9% to 54.8%, p0.001). Life-threat-
ening outcomes increased for melphalan/leukemia (0% to 17.7%, p0.016), mel-
phalan/chromosomal aberrations (0 to 8.7%, p0.001), carmustine leukopenia (0
to 17.7%, p0.016), and carmustine/thrombocytopenia (0-20.3%, P0.045).
CONCLUSIONS: Prior to the BBWs, health professionals do not appear to associate
the ADRs with the drug and/or do not report the events to the FDA. Issuance of
BBWs appears to result in increased awareness and reporting. Since pre-marketing
research may not identify rare ADRs and voluntary post-marketing reporting may
be inadequate, proactive pharmacovigilance programs should be implemented.
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OBJECTIVES: 1) Examine survival of late stage prostate cancer patients; and 2)
Determine factors associated with survival at both the patient and neighborhood
levels. METHODS: Prostate cancer cases were obtained from the Florida Cancer
Data System. Men aged 40 years and above diagnosed with late prostate cancer in
1995 were followed through 2000. Demographics, health insurance and vital sta-
tistics were extracted for individual patients and linked with Florida Census 2000
data with education and poverty level information. Data was analyzed using a
multilevel logistic regression to examine the relationship of prostate cancer sur-
vival with both patient-level characteristics and area-based measures of socioeco-
nomic status.RESULTS:Atotal of 1,101menwerediagnosed in Floridawith late stage
prostate cancer in 1995 with an average age of 69 years. Patients with the following
characteristics were more likely to die from prostate cancer than their counterparts:
unmarried, Medicaid recipient, and older. Men residing in neighborhood with higher
percentage of high school education and surprisingly men without health insurance
weremore likely to live longer than five years.CONCLUSIONS: Although survival has
improvedover timedue to early detectionof prostate cancer, there are still differences
in survival among men diagnosed with late stage based on different marital status,
health insurance and neighborhood characteristics.
Cancer – Cost Studies
PCN25
BUDGET-IMPACT OF ERIBULIN FOR THIRD-LINE TREATMENT OF METASTATIC
BREAST CANCER IN A UNITED STATES MANAGED CARE SETTING
Tao C1, Taylor D1, Parthan A2, Faria C3, Choe Y3
1i3 Innovus, Medford, MA, USA, 2i3 Innovus, San Francisco, CA, USA, 3Eisai, Inc., Woodcliff
Lake, NJ, USA
OBJECTIVES: Eribulin is a non-taxane microtubule dynamics inhibitor that has
demonstrated improved overall survival in a phase III study relative to commonly
used therapies in late-line metastatic breast cancer (MBC). This budget impact
model (BIM) was developed to help US payers make informed decisions regarding
addition of eribulin for the management of MBC.METHODS: From the perspective
of US commercial payers, an Excel-based BIMwas constructed upon a hypothetical
plan of 1 million members. 600 women are estimated to be newly diagnosed with
breast cancer; of these 5% with MBC and 24% are initiated on 3rd-line chemother-
apy, 47% of these on monotherapy. A Markov decision-analytic model was used to
tracemovement of patients receiving eribulin or another 3rd-line single-agent che-
motherapies through different MBC states (treatment initialization, stable, re-
sponse, progression, death). The model used a two-year time horizon with one-
week Markov cycle lengths. The efficacy, market shares, and medical and drug
costs were derived using published and internally available data sources. Model
probabilities were based on discontinuation, progression free survival, and overall
survival rates from the EMBRACE trial. Market share of eribulin was assumed to be
5% in year-one and 10% in year-two of the model. Model outcomes included: total
costs over 2 years pre- and post-inclusion of eribulin, net costs, cost per member
permonth (PMPM), cost per patient permonth (PPPM) andmedian overall survival.
RESULTS: Of the 1 million plan members, approximately 3 incident cases of MBC
requiring 3rd line treatment were identified each year. Budgetary impact PMPM
was estimated to be $0.01 in year-one and year-two, and PPPM $118 and $252,
respectively. Overall net budgetary impact for year-one and year-two was $4,880
and $10,450, respectively. CONCLUSIONS: Based on this analysis adding eribulin
does not exhibit a significant overall cost increase when taking into account med-
ical and drug expenditures.
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OBJECTIVES: Skeletal complications from bonemetastases can be debilitating and
costly. Denosumab was recently approved in the US for SRE prevention in patients
with bonemetastases from solid tumors. This study evaluated the three-year bud-
get impact of denosumab compared to zoledronic acid (ZA) for breast and prostate
cancer using the US managed care perspective. METHODS: Excel-based models
compared denosumab (120mg) to ZA (4 mg) administered every four weeks for the
patient lifetime. Inputs included the US population age and gender distribution,
Medicare managed care enrollment rates, the prevalence of bone metastases (es-
timated from literature-based epidemiological simulations), and 2010 costs for
therapy and SREs. Utilization estimates assumed that 66% of breast and 48% of
prostate cancer patients with bone metastases would receive anti-resorptive ther-
apy and that for years one to three 20%, 35% and 45% of these patients would use
denosumab. Trial-based SRE rates per patient-year were 0.488 and 0.631 (deno-
sumab and ZA) for breast cancer and 0.746 and 0.947 for prostate cancer. The
expected incremental adverse event cost was nominal and therefore excluded.
Sensitivity analyses were conducted to identify influential variables on the incre-
mental costs per member per month (PMPM). RESULTS: The incremental PMPM
costs for years one to three were $0.02, $0.04, and $0.05 ($0.11 total) for breast
cancer and $0.01, $0.02, and $0.03 ($0.06 total) for prostate cancer. For both tumor
types, influential variables included costs for denosumab and ZA, prevalence rates
of each cancer and of bonemetastases, utilization rates of denosumab and ZA, and
underlying SRE rates. The younger breast cancer age distribution results in a larger
incremental cost burden for managed care organizations when compared to pros-
tate cancer. CONCLUSIONS: The real-world financial impact to US health plans
from using denosumab should be relatively modest and will vary depending on
prevalence and utilization patterns.
PCN27
COMPARATIVE BUDGET IMPACT OF FORMULARY INCLUSION OF ZOLEDRONIC
ACID AND DENOSUMAB FOR PREVENTION OF SKELETAL-RELATED EVENTS IN
PATIENTS WITH BONE METASTASES
Bell MJ1, Miller JD2, Namjoshi M3, Russell MW2
1RTI Health Solutions, Manchester, UK, 2RTI Health Solutions, Waltham, MA, USA, 3Novartis
Oncology US, East Hanover, NJ, USA
OBJECTIVES: Skeletal complications from bone metastases impose a significant
clinical and economic burden on patients and health systems. Zoledronic acid (ZA)
has been the mainstay for prevention of skeletal related events (SREs) in patients
with bonemetastases. In 2010, FDA approved denosumab for prevention of SREs in
patients with solid-tumor bone metastases. We assessed the financial impact to a
managed-care plan of adding denosumab to a ZA-only formulary for this
indication.METHODS:We developed an Excel-based model to evaluate the trajec-
tory of spending over 1-3 year time horizons in a hypothetical managed care plan
with 1 million members and 688 patients with solid-tumor bone metastases. The
model considered use and associated costs of drug acquisition and administration,
SRE management, and adverse event (AE) treatment under two scenarios: (1) Base
Case—ZA-only formulary; and (2) Restricted Formulary—denosumab limited to sec-
ond-line treatment in patients failing ZA. SREs included pathologic fracture, ther-
apeutic radiology, spinal cord compression, and orthopaedic surgery. AEs included
osteonecrosis of the jaw, renal problems, acute phase reactions, andhypocalcemia.
Model parameters were derived from published literature, product labels, clinical
trial data, and administrative cost databases. Drug costs were based on published
wholesale acquisition cost minus copayments. Costs were stated as 2010 US
dollars. RESULTS: In the Base Case scenario (ZA only), total costs were $10.8 million
per year. Allowing restricted access to denosumab was associated with total
costs of $11.4, $11.6, and $11.7 million over 1, 2, and 3 years ($0.05, $0.06, $0.08
incrementally per-member per-month). The corresponding incremental cost of
adding denosumab was $69, $94, and $115 per ZA-treated member per month.
CONCLUSIONS:With an acquisition cost nearly twice that of ZA, restricted use of
denosumab adds considerably to patient management costs. Incremental benefits
should be weighed carefully against these costs before considering coverage.
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OBJECTIVES: To evaluate the economic impact of intravenous iron (ferric carboxy-
maltose; Ferinject) in chemotherapy-induced ferriprive anemia in breast and gas-
trointestinal cancer.METHODS:We used an economicmodel which compared the
usual therapeutic strategies of anemia with or without intravenous iron. Costs
related to anemia treatment by ESA, blood transfusion and intravenous iron were
estimated and compared. Cost savingswere calculated from the French healthcare
payer perspective. Data included in the economic model were obtained from sci-
entific literature, public health agencies and medical experts. Impact of Ferinject
on the decrease of the number of blood transfusions at hospital and the decrease of
ESA dosing was evaluated. RESULTS: Patients treated with 2000 mg of Ferinject
during chemotherapy treatment and 1000 mg at home concomitantly with ESA
once every two month during 4 months. Based on the estimated decreased of the
25% ESA dosing when administered with Ferinject, and a decrease of 10% of pa-
tients receiving ESA after chemotherapy (expert opinion), the most prominent an-
nual cost savings were observed in chemotherapy-induced anemia in breast can-
cer (€881 and €319 by patient for metastatic and non-metastatic breast cancers,
respectively); global cost saving is estimated to €29millions. Regarding blood trans-
fusion the cost saving is estimated to €1.6 millions. Impact of Ferinject on the
decrease of ESA dosing in gastrointestinal cancer was evaluated on the same basis.
The annual cost saving is estimated to €6.6 millions. Analysis showed that strate-
gies including intravenous iron remained cost-effective even with wide variations
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